(NASDAQ: FHTX) Foghorn Therapeutics's forecast annual revenue growth rate of 10.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Foghorn Therapeutics's revenue in 2026 is $28,224,000.On average, 12 Wall Street analysts forecast FHTX's revenue for 2026 to be $1,555,566,649, with the lowest FHTX revenue forecast at $188,001,978, and the highest FHTX revenue forecast at $2,457,295,064. On average, 12 Wall Street analysts forecast FHTX's revenue for 2027 to be $2,223,731,082, with the lowest FHTX revenue forecast at $1,150,792,871, and the highest FHTX revenue forecast at $3,157,634,725.
In 2028, FHTX is forecast to generate $2,113,525,050 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $5,116,155,021.